Table 2.

Patient demographics.

CharacteristicETN, n = 218ETN/MTX, n = 229All, n = 447
Mean age, yrs (range)54.3 (21–88)54.7 (19–82)54.5 (19–88)
Sex, n (%)
  Men40 (18.3)53 (23.1)93 (20.8)
  Women178 (81.7)176 (76.9)354 (79.2)
Race, n (%)
  White176 (80.7)188 (82.1)364 (81.4)
  Black17 (7.8)11 (4.8)28 (6.3)
  Hispanic21 (9.6)22 (9.6)43 (9.6)
  Asian3 (1.4)5 (2.2)8 (1.8)
  American Indian or Alaska Native1 (0.5)1 (0.4)2 (0.4)
  Other0 (0.0)2 (0.9)2 (0.4)
Age, yrs, n (%)
  < 65169 (77.5)174 (76.0)343 (76.7)
  ≥ 6549 (22.5)55 (24.0)104 (23.3)
Mean weight, kg (SD)78.9 (20.2)*82.3 (25.4)80.7 (23.1)
Mean height, cm (SD)164.8 (8.5)*166.5 (9.6)165.7 (9.1)
Mean BMI, kg/m2 (range)29.0 (18.0–50.3)*29.5 (15.7–67.2)29.3 (15.7–67.2)
Mean C-reactive protein, mg/l (SD)16.4 (20.9)14.4 (29.9)ND
Mean tender joint count (0–68), (SD)23.7 (15.7)21.5 (16.8)22.6 (16.3)
Median tender joint count (0–68), (range)21.5 (0–68)19.0 (0–68)21.0 (0–68)
Mean swollen joint count (0–66), (SD)14.5 (9.6)13.3 (9.1)13.9 (9.4)
Median swollen joint count (0–66), (range)13.0 (0–50)11.0 (0–50)21.0 (0–50)
Mean HAQ (SD)1.4 (0.7)1.3 (0.7)1.3 (0.7)
Mean DAS28 (SD)5.4 (1.3)5.0 (1.3)5.2 (1.3)
Mean Pt-DAS28 (SD)5.5 (1.3)5.1 (1.4)5.3 (1.3)
Mean patient global assessment of disease activity (SD); scale 0–10058.7 (23.4)*53.7 (24.0)56.1 (23.8)
Mean physician global assessment of disease activity (SD); scale 0–10055.1 (22.6)51.9 (24.9)53.5 (23.9)
  • * n = 217. BMI: body mass index; DAS28: disease activity score; ETN: etanercept; HAQ: Health Assessment Questionnaire; MTX: methotrexate; ND: not determined; Pt-DAS28: patient-derived DAS28.